The circulating levels of adiponectin, an adipocyte-derived hormone, have been demonstrated to be decreased in patients with the phenotypes of metabolic syndrome[2], including obesity[3], type 2 diabetes (T2DM)[4], and insulin resistance[5]. This evidence concerns the gene ADIPOQ and metabolic syndrome.